Pharvaris N.V. Ordinary Shares
PHVSPharvaris N.V. is a biopharmaceutical company focused on developing therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by severe swelling episodes. The company's approach involves targeting the kallikrein-kinin system to develop innovative treatments that address the underlying causes of HAE. Headquartered in the Netherlands, Pharvaris aims to improve the quality of life for patients through its pipeline of novel oral and injectable therapies.
Company News
Pharvaris N.V., a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for hereditary angioedema and acquired angioedema, announced the pricing of an underwritten public offering of approximately 3.87 million ordinary shares at $29.68 per share, generating approximately $115 million in gross proceeds. The offeri...
Director Johannes Gerardus Christiaan Petrus Schikan sold 7,100 shares of Pharvaris (1.80% of his direct holdings) for approximately $213,000 under a pre-scheduled trading plan. The modest sale is not indicative of any change in outlook. Investors should focus instead on upcoming clinical catalysts: Phase 3 CHAPTER-3 topline data expected in Q3 2...
Bain Capital Life Sciences Investors sold 122,106 shares of Pharvaris N.V. during Q3 2025, reducing its position value by $21.23 million while maintaining a significant stake. The sale appears to be profit-taking rather than a negative sentiment shift.
Pharvaris, a biopharmaceutical company, has priced a public offering of 8,250,000 ordinary shares at $20.00 per share and pre-funded warrants to purchase 500,000 shares, expecting to raise approximately $175 million.
Pharvaris presented data at the EAACI Congress 2025 supporting the potential of its oral bradykinin B2 receptor antagonist, deucrictibant, for the prophylactic and on-demand treatment of bradykinin-mediated angioedema attacks.
